Free Trial

Cellebrite DI Ltd. (NASDAQ:CLBT) is Greenhaven Road Investment Management L.P.'s 3rd Largest Position

Cellebrite DI logo with Business Services background

Greenhaven Road Investment Management L.P. lowered its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 9.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,858,268 shares of the company's stock after selling 314,339 shares during the period. Cellebrite DI makes up 11.1% of Greenhaven Road Investment Management L.P.'s portfolio, making the stock its 3rd biggest position. Greenhaven Road Investment Management L.P. owned approximately 1.52% of Cellebrite DI worth $24,753,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the business. IGP Investments G.P.L.P LP bought a new position in shares of Cellebrite DI during the 4th quarter valued at about $182,619,000. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Cellebrite DI by 7.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 7,086,158 shares of the company's stock valued at $56,446,000 after purchasing an additional 514,858 shares in the last quarter. Crosslink Capital Inc. lifted its holdings in shares of Cellebrite DI by 1.4% during the 4th quarter. Crosslink Capital Inc. now owns 3,240,480 shares of the company's stock valued at $28,063,000 after purchasing an additional 44,520 shares in the last quarter. Voss Capital LLC raised its position in Cellebrite DI by 207.7% in the 4th quarter. Voss Capital LLC now owns 1,835,000 shares of the company's stock valued at $15,891,000 after buying an additional 1,238,580 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Cellebrite DI by 295.6% in the 3rd quarter. Acadian Asset Management LLC now owns 1,646,480 shares of the company's stock valued at $12,563,000 after buying an additional 1,230,244 shares during the last quarter. Institutional investors own 45.88% of the company's stock.


Cellebrite DI Trading Down 2.0 %

Shares of NASDAQ:CLBT traded down $0.25 during trading on Thursday, hitting $12.25. 1,633,935 shares of the company were exchanged, compared to its average volume of 932,510. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of -21.55, a P/E/G ratio of 1.62 and a beta of 1.48. Cellebrite DI Ltd. has a fifty-two week low of $6.08 and a fifty-two week high of $12.67. The firm has a fifty day moving average price of $11.01 and a two-hundred day moving average price of $10.19.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Thursday, May 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. The firm had revenue of $89.60 million for the quarter, compared to analyst estimates of $85.34 million. Cellebrite DI had a positive return on equity of 417.94% and a negative net margin of 32.57%. The business's quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.03 EPS. As a group, research analysts predict that Cellebrite DI Ltd. will post 0.33 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on CLBT shares. Lake Street Capital started coverage on Cellebrite DI in a research report on Friday, April 19th. They issued a "buy" rating and a $13.00 target price on the stock. Bank of America lifted their target price on Cellebrite DI from $12.00 to $13.00 and gave the company a "buy" rating in a research report on Monday, April 1st. JPMorgan Chase & Co. lifted their target price on Cellebrite DI from $12.00 to $14.00 and gave the company an "overweight" rating in a research report on Friday, May 24th. Needham & Company LLC lifted their target price on Cellebrite DI from $13.50 to $14.00 and gave the company a "buy" rating in a research report on Friday, May 24th. Finally, Craig Hallum lifted their target price on Cellebrite DI from $14.00 to $16.00 and gave the company a "buy" rating in a research report on Monday, April 1st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cellebrite DI currently has an average rating of "Buy" and a consensus target price of $13.17.

Get Our Latest Stock Report on CLBT

Cellebrite DI Company Profile

(Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Featured Articles

Institutional Ownership by Quarter for Cellebrite DI (NASDAQ:CLBT)

Should you invest $1,000 in Cellebrite DI right now?

Before you consider Cellebrite DI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.

While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines